

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following proteins is targeted by the monoclonal antibody seribantumab?
 - a. IDH1/2
 - b. HER3**
 - c. FGFR2
 - d. PI3K

2. What was the approximate duration of response observed for patients with previously treated advanced cholangiocarcinoma and FGFR2 fusions/rearrangements receiving pemigatinib in the Phase II FIGHT-202 trial?
 - a. 4 months
 - b. 9 months**
 - c. 18 months

3. Which of the following is a class effect of FGFR inhibitors?
 - a. Hyperphosphatemia**
 - b. Cytokine release syndrome
 - c. Retinal degeneration
 - d. Ventricular systolic dysfunction

4. What was the approximate reduction in the risk of death with cabozantinib in a retrospective analysis of the Phase III CELESTIAL trial for patients with previously treated advanced hepatocellular carcinoma who experienced progression to Child-Pugh B cirrhosis by week 8?
 - a. 25%
 - b. 50%
 - c. 70%**

5. What was the approximate overall response rate observed with seribantumab for patients with solid tumors and NRG1 fusions in the Phase II CRESTONE trial?
 - a. 10% to 15%
 - b. 30% to 35%**
 - c. 65% to 70%